glp 1 diabetes GLP-1 One in 10 people may
Description
How we source info
Kosei, T
Financial Times reported this week that Lilly and Novo, the manufacturers of all four GLP-1 drugs commonly used for obesity therapy, are spending $3.5 billion this year to purchase smaller companies with promising anti-obesity therapies
The trials were well-designed, the results compelling
doi: 10.1161/ATVBAHA.110.222653
Knudsen LB, Lau J
